Stereotactic body radiation therapy for liver primary and metastases: The Lille experience;Radiothérapie stéréotaxique hépatique par CyberKnife ®: L'expérience lilloise

Cancer/Radiotherapie

Volumn 16, Issue 1, 2012, Pages 58-69

  Dewas, S ^a,b   Mirabel, X ^a,b   Kramar, A ^a   Jarraya, H ^a   Lacornerie, T ^a,b   Dewas Vautravers, C ^a,b   Fumagalli, I ^a,b   Lartigau, É ^a,b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b UNIV LILLE   (France)

Author keywords

CyberKnife ; Hepatocarcinoma; Liver mestastases; Local control; Stereotactic body radiation therapy; Toxicities

Indexed keywords

GOLD;

ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; GASTRODUODENAL ULCER; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; FRANCE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84857408208     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.06.005     Document Type: Article

References (43)

1. Hennequin C., Quero L., Rivera S. Radiosensibilité des cancers du foie. Cancer Radiother 2011, 15:9-42.
2. De Bari B., Pointreau Y., Rio E., Mirabel X., Mornex F. Dose de tolérance à l'irradiation des tissus sains: le foie. Cancer Radiother 2010, 14:344-349.
3. ® robotic system. Cancer Radiother 2006, 10:283-287.
4. ®: aspects techniques et indications. Cancer Radiother 2007, 11:338-344.
5. Louis C., Dewas S., Mirabel X., Lacornerie T., Adenis A., Bonodeau F., et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 2010, 9:479-487.
6. Vautravers-Dewas C., Dewas S., Bonodeau F., Adenis A., Lacornerie T., Penel N., et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose-response relationship?. Int J Radiat Oncol Biol Phys 2011, 81:e39-e47.
7. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
8. CTCAEv3.0. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2010.
9. Cardenes H.R., Price T.R., Perkins S.M., Maluccio M., Kwo P., Breen T.E., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-225.
10. Choi B.O., Choi I.B., Jang H.S., Kang Y.N., Jang J.S., Bae S.H., et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 2008, 8:351.
11. Goodman K.A., Wiegner E.A., Maturen K.E., Zhang Z., Mo Q., Yang G., et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:486-493.
12. Méndez Romero A., Wunderink W., Hussain S.M., De Pooter J.A., Heijmen B.J., Nowak P.C., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006, 45:831-837.
13. Tse R.V., Hawkins M., Lockwood G., Kim J.J., Cummings B., Knox J., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664.
14. Blomgren H., Lax I., Göranson H., Krsgmaeligpelien T., Nilsson B., Näslund I. Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurg 1998, 1:63-74.
15. Wulf J., Guckenberger M., Haedinger U., Oppitz U., Mueller G., Baier K., et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006, 45:838-847.
16. Dawson L.A., McGinn C.J., Normolle D., Ten Haken R.K., Walker S., Ensminger W., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
17. Park H.C., Seong J., Han K.H., Chon C.Y., Moon Y.M., Suh C.O. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:150-155.
18. Herfarth K.K., Debus J., Lohr F., Bahner M.L., Rhein B., Fritz P., et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
19. Cheng J.C., Wu J.K., Huang C.M., Liu H.S., Huang D.Y., Tsai S.Y., et al. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2003, 56:229-234.
20. Guo W.J., Yu E.X., Liu L.M., Li J., Chen Z., Lin J.H., et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003, 9:1697-1701.
21. Yamada K., Izaki K., Sugimoto K., Mayahara H., Morita Y., Yoden E., et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003, 57:113-119.
22. Mornex F., Girard N., Beziat C., Kubas A., Khodri M., Trepo C., et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66:1152-1158.
23. Fuss M., Salter B.J., Herman T.S., Thomas C.R. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology 2004, 127:S206-S217.
24. Kato H., Tsujii H., Miyamoto T., Mizoe J.E., Kamada T., Tsuji H., et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004, 59:1468-1476.
25. Fukumitsu N., Sugahara S., Nakayama H., Fukuda K., Mizumoto M., Abei M., et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009, 74:831-836.
26. Milano M.T., Katz A.W., Muhs A.G., Philip A., Buchholz D.J., Schell M.C., et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008, 112:650-658.
27. Hoyer M., Roed H., Traberg Hansen A., Ohlhuis L., Petersen J., Nellemann H., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45:823-830.
28. Herfarth K.K., Debus J. Stereotactic radiation therapy for liver metastases. Chirurg 2005, 76:564-569.
29. Lee M.T., Kim J.J., Dinniwell R., Brierley J., Lockwood G., Wong R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591.
30. Katz A.W., Carey-Sampson M., Muhs A.G., Milano M.T., Schell M.C., Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007, 67:793-798.
31. Schefter T.E., Kavanagh B.D., Timmerman R.D., Cardenes H.R., Baron A., Gaspar L.E. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005, 62:1371-1378.
32. Wada H., Takai Y., Nemoto K., Yamada S. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys 2004, 58:1114-1120.
33. Wulf J., Hadinger U., Oppitz U., Thiele W., Ness-Dourdoumas R., Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001, 177:645-655.
34. Rusthoven K.E., Kavanagh B.D., Cardenes H., Stieber V.W., Burri S.H., Feigenberg S.J., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578.
35. Ambrosino G., Polistina F., Costantin G., Francescon P., Guglielmi R., Zanco P., et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 2009, 29:3381-3384.
36. van der Pool A.E., Méndez Romero A., Wunderink W., Heijmen B.J., Levendag P.C., Verhoef C., et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010, 97:377-382.
37. Blomgren H., Lax I., Naslund I., Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870.
38. Kavanagh B.D., Schefter T.E., Cardenes H.R., Stieber V.W., Raben D., Timmerman R.D., et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006, 45:848-855.
39. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
40. El-Serag H.B., Davila J.A., Petersen N.J., McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
41. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353-1357.
42. Nordlinger B., Guiguet M., Vaillant J.C., Balladur P., Boudjema K., Bachellier P., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association française de chirurgie. Cancer 1996, 77:1254-1262.
43. Fuss M., Thomas C.R. Stereotactic body radiation therapy: an ablative treatment option for primary and secondary liver tumors. Ann Surg Oncol 2004, 11:130-138.